

CombiGene requests initiation of compulsory acquisition proceeding of shares and warrants in Panion

CombiGene has become the owner of more than 90 percent of the shares in Panion. CombiGene has requested initiation of compulsory acquisition proceeding to acquire all remaining shares and warrants in Panion and will promote a delisting of Panion's shares and warrants from Spotlight.

Panion Animal Health AB (publ) ("**Panion**") has previously announced that CombiGene AB (publ) ("**CombiGene**") holds more than 90 percent of the outstanding shares in Panion.

Through CombiGene's public offer as of 18 April 2019, the issue of new shares that Panion completed to CombiGene on 30 August 2019 and through the purchase of shares on the market, CombiGene now holds 91.42 percent of the outstanding shares in Panion. Furthermore, CombiGene holds 84.91 percent of Panion's warrants of series TO1 ("**Warrants**").

CombiGene has requested initiation of compulsory acquisition proceeding to acquire all remaining shares and Warrants in Panion in accordance with the Companies Act (2005:551). In connection to this, CombiGene intends to, as specified in the press release regarding the public offer, promote a delisting of Panion's shares and Warrants from Spotlight Stock Market.

For further information, please contact:

Jan Nilsson (CEO)
Telephone: +46704663163
E-mail: jan.nilsson@combigene.com

Arne Ferstad (Chairman of the Board)
Telephone: +447496526142
E-mail: arne.ferstad@ankor-consultants.com

The information was submitted for publication, through the agency of Jan Nilsson, on 13 September 2019, 08.15 CEST.

Contacts

Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
Email: jan.nilsson@combigene.com

www.combigene.com
CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com

About CombiGene

CombiGene's vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.

CombiGene's business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

Attachments

[CombiGene requests initiation of compulsory acquisition proceeding of shares and warrants in Panion](#)